611 W. Union Street
Benson, AZ 85602
(520) 586-0800

LaFrontera
member support line
1-520-279-5737
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Smog Tied to Raised Risk for Parkinson's, Alzheimer's DiseaseWhat Will Convince Americans to Get a COVID-19 Vaccine?Curbing COVID Brought Unexpected Benefit for Asthma Patients1 in 3 Americans With Arthritis Say Pain, Symptoms PersistCDC Recommends Face Masks in All Public Transportation SettingsIn Medieval Times, Plagues 'Sped Up' With Each New OutbreakWhat You Need to Know About Your Colon Cancer RiskNewer Rheumatoid Arthritis Drug May Help Ease Tough-to-Treat CasesCelebrate Autumn Traditions Without Raising Your COVID RiskNew Drug Could Extend Life for People With ALSHeart Defects Don't Increase Risk of Severe COVID-19Chinese COVID Vaccine Shows Promise in Early TrialAmerica Sees Daily COVID Cases Pass 60,000 Once AgainCOVID Scored Big at 'Superspreader' Hockey GameAHA News: Belly Fat May Signal Early Heart Issues for Mexican AmericansFDA Approves First Ebola Virus TreatmentAmericans Might Need to Pass on Thanksgiving Gatherings: FauciAHA News: Flu and COVID-19 Are Bad Enough, But They Also Can Raise Stroke RiskYour Blood Type May Predict Your Risk For Severe COVID-19Newborns of Moms With COVID-19 Face Little Infection Risk: StudyCOVID Cases Climbing in 36 StatesBedside COVID-19 Test Faster Than Standard PCR TestNIH Launches Trial of Antibody Drugs Against COVID-19Long-Lasting Immunity Seems to Follow Serious COVID CasesAHA News: How Much Do You Know About Thrombosis? Probably Not EnoughCOVID-19 Taking Huge Toll in Excess U.S. DeathsSecond COVID Vaccine Trial Paused for Unexplained IllnessBlacks, Asians More Likely Than Whites to Have Severe COVIDUpper Midwest Sees COVID-19 Surge as Northeast Worries About a Second WaveRemdesivir Speeds Recovery for COVID PatientsAnimal Study Points to Heating Coil Behind Serious Vaping InjuriesAHA News: Strokes and Heart Attacks Increase When Flu-Like Illnesses RiseZika Epidemic Was More Widespread Than Thought: StudyVirtual Care After Surgery May Be More Convenient For PatientsAlways Be Ready for a Trip to the ERPandemic Silver Lining: Steep Drop in Kids' FracturesAntibiotics May Be Best First Treatment for AppendicitisResearchers Identify Bacteria Responsible for Key Crohn's ComplicationDuring and After Surgery, Pot Users Need More Anesthesia, Painkillers: StudyHeart Patients Need to Be Wary of CoronavirusWearing a Mask Doesn't Cause CO2 PoisoningCOVID-19 ICU Patients Have High Risk of Clots, Research ShowsGot Sciatica? Stay Active and Start Early on Physical TherapyDrug Combo Approved for First-Line Treatment of Mesothelioma8 in 10 COVID-19 Patients Suffer Neurological Symptoms, Study FindsAs Virtual Doctor Visits Spike, Concerns About Equity, Missed Diagnoses GrowFor Maximum Safety, Be Sure to Wash Your Homemade Face Mask: StudyDo Minority Kids Face More Danger During Surgeries?Why Getting a Flu Shot is More Important Than Ever This FallCommon Heartburn Meds Tied to Higher Diabetes Risk
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Another Rapid COVID-19 Test Shows Promise

HealthDay News
by -- Robert Preidt
Updated: Sep 18th 2020

new article illustration

FRIDAY, Sept. 18, 2020 (HealthDay News) -- Yet another rapid COVID-19 test has proven its mettle in spotting infection with the new coronavirus, this time in a British study.

The lab-in-a-cartridge testing device -- which can be performed at bedside, doesn't require a laboratory, and can be performed in cartridges smaller than a mobile phone -- was tested on 386 National Health Service staff and patients in Britain.

The test had 94% sensitivity and 100% specificity, meaning it had a high level of accuracy and produced very few false negatives and no false positives. The results are available within 90 minutes, while conventional COVID-19 tests provide results within 24 hours, the researchers said. The findings were published Sept. 17 in The Lancet Microbe journal.

In the United States, four rapid coronavirus tests have already been developed. These tests detect COVID-19 antigens, proteins found on the surface of the coronavirus, rather than the virus itself, according to the Associated Press. It's considered a faster, but less precise, screening method.

One of these tests, made by Abbott Laboratories and called BinaxNOW, has already secured a $760 million deal with the White House to produce 150 million rapid nasal swab tests for community testing, according to the AP.

The 15-minute BinaxNOW test will sell for $5, giving it an edge over similar tests that need to be popped into a small machine, the AP reported. No larger than a credit card, the Abbott test is based on the same technology used to test for the flu, strep throat and other infections.

"Those [rapid] screening tests are what we need in schools, workplaces and nursing homes in order to catch asymptomatic spreaders," Dr. Jonathan Quick, an adjunct professor of global health at Duke University in North Carolina, told the AP.

With the British test, a nose swab from a patient is inserted into the cartridge device, which analyzes the sample for genetic material belonging to SARS-CoV-2 virus.

The new test is being used at eight London hospitals, and is due to be rolled out at a national level. The U.K. government recently placed an order for 5.8 million of the testing kits.

"These results suggest the test, which can be performed at a patient's bedside without the need to handle any sample material, has comparable accuracy to standard laboratory testing," said study author Graham Cooke. He is a professor in the department of infectious disease at Imperial College London.

"Many tests involve a trade-off between speed and accuracy, but this test manages to achieve both," Cooke said in a college news release.

The test -- made by DnaNudge, an Imperial College London start-up -- is now being developed to simultaneously check for COVID-19, influenza and respiratory syncytial virus, the researchers added.

Chris Toumazou is CEO and co-founder of DnaNudge and founder of the Institute of Biomedical Engineering at Imperial College London. He said, "The DnaNudge test was developed as a lab-free, on-the-spot consumer service that can be delivered at scale, so we clearly believe it offers very significant potential in terms of mass population testing during the COVID-19 pandemic."

More information

The U.S. Centers for Disease Control and Prevention has more on COVID-19 testing.